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ABSTRACT 
 
Objectives: The main goal of this study was to differentiate patients with amnestic mild cog-
nitive impairment (aMCI) or Alzheimer disease (AD) from patients with vascular cognitive 
impairment (VCI) or vascular dementia (VaD) based on the new developed Visual association 
test (VAT) recognition trial. Furthermore, the score difference between the VAT immediate 
recall trial two to the VAT delayed recall trial and the score difference between the VAT im-
mediate recall trial two to the VAT recognition trial in comparison to the score difference of 
the VAT immediate recall trials (one and two). Last, we evaluated the visual VAT recognition 
trial in comparison to the 15 word task (15WT) recognition trial for each group.  
Methods: We evaluated 55 geriatric outpatients and nursing home day care patients (19 with 
aMCI, 25 with AD, 6 with VCI, and 5 with VaD). Because of the low number of patients, we 
compared the patients with aMCI or AD (n = 44) and the patients with VCI or VaD (n = 11). 
We used the VAT and the 15WT. The non-parametric Mann-Whitney U-test and the Wilcox-
on signed-ranks test were used to analyze data. 
Results: We found that patients with aMCI or AD and patients with VCI or VaD perform 
equally based on the VAT recognition trial. By contrast, we found that patients with aMCI 
perform relatively better than patients with AD. Furthermore, we found that all patients except 
patients with VaD show an improvement on the VAT immediate recall trials and deterioration 
on the VAT delayed recall trial. All patients perform equally on the VAT recognition trial in 
comparison to the VAT immediate recall trial. As last, we found that patients with aMCI or 
AD and aMCI separately perform relatively better on the visual (VAT) recognition in compar-
ison to the verbal (15WT) recognition trial. 
Conclusion:  We may conclude that, based on these data there’s no differentiation possible 
between patients with aMCI or AD and patients with VCI or VaD based on the VAT recogni-
tion trial.  
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1. INTRODUCTION 
  Dementia is prevalent in old age, with approximately one percent affected of people 
aged 65 or over and approximately 25% of those aged 85 or over (Ferri et al., 2005). Cogni-
tive impairment is the core clinical symptom of dementia. However, cognitive symptoms may 
differ across dementia type etiologies. Neuro-degenerative disease is an umbrella term for the 
progressive loss of structure or function of neurons. The most common form of neurodegen-
erative disease is Alzheimer’s disease (AD; 50-75%; World Alzheimer report, 2009). Cere-
brovascular disease (CVD) is an umbrella term for conditions caused by problems with brain 
vasculature. Vascular dementia (VaD) is resulting from CVD and ischemic or hemorrhagic 
brain injury. VaD is the second most common type of dementia (2.2%-16.3%; Leys, Pasquier 
& Parnetti, 1998).  Mild cognitive impairment (MCI) and vascular cognitive impairment 
(VCI) are defined as a decline in cognition and function but that do not meet criteria for the 
diagnosis of dementia. Episodic memory impairment is prevalent in amnestic Mild Cognitive 
Impairment (aMCI) or Alzheimer disease (AD) and impaired attention, mental speed, and 
retrieval deficits often characterize Vascular cognitive impairment (VCI) or Vascular Demen-
tia (VaD). A recent study of 15.367 patients with VaD reported that 16.6% were miss diag-
nosed with AD (Kirson et al., 2013). It’s predicted that discriminating AD from VaD is possi-
ble with recognition trials, because the recognition of VaD patients is normal, whereas AD 
patients show impaired recognition (Lafosse et al., 1997). Neuropsychological tests such as 
the Visual Association Test (VAT) are useful in assessing episodic memory deficits (Linde-
boom & Schmand, 2003). Recently, a VAT recognition task (Meyer, Spaan, Boelaarts, 
Schmand, & de Jonghe, in preparation) was constructed with the aim of expanding clinical 
assessment of different types of memory impairment. They developed these new parallel ver-
sions because most of the current tests (e.g. the Rey Auditory Verbal Learning Test; RAVLT 
or the Dutch version 15 word task; 15WT) may result in floor effects to patients with amnes-
tic mild cognitive impairment (aMCI) or AD (Kessels, Rijken, Joosten-Weyn Banningh, 
Schuylenborgh-van Es & Olde Rikkert, 2009; Petersen et al., 1999; Ricci, Graef, Blundo & 
Miller, 2012). A floor effect refers to the diminished ability of a test to differentiate between 
persons at the low end of the measurement range (Cohen, Swerdlik & Sturman, 2013). Alt-
hough the new VAT recognition task has been studied in normal controls, it’s usefulness in 
clinical populations still awaits evaluation. Therefore, this study evaluated the differences 
between older patients with aMCI or AD in comparison to patients with VCI or VaD based on 
the VAT recognition trial. Furthermore, we evaluated in a exploratory manner the comparison 
of the VAT trials and we made a comparison of the VAT recognition trial with the 15 word 
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task for those group. 
 
1.1 Memory and Brain Structures 
  An important neurological structure for memory is the medial temporal lobe (MTL). 
The MTL includes a system of anatomical related structures that are essential for declarative 
memory. Declarative memory can be broken down further into things that we recall about our 
own lives (episodic memory) and world knowledge (semantic memory). The MTL can be 
subdivided into the perirhinal cortex, the parahippocampal cortex, the entorhinal cortex and 
the hippocampus (Eichenbaum, Yonelinas & Ranganath, 2007).  Regional atrophy of the 
MTL, particularly the hippocampus and the entorhinal cortex is present in 80-90% of AD pa-
tients, opposed to 5-10% of healthy aged-controls (Scheltens et al., 1992). The hippocampus 
is critical for storing new memories. The hippocampal volume of patients with AD is reduced 
with 16.6% and the hippocampal volume of patients with VaD is reduced with 11.6% (van de 
Pol, Gertz, Scheltens & Wolf, 2011). Thus, the hippocampus is also affected, but rarely does a 
deficit of episodic memory in these patients reach the severity presented in typical AD (Gra-
ham, Emery, & Hodges, 2004; Lafosse et al., 1997; Lamar et al., 1997). The damage to the 
hippocampus is correlated with performance on memory tests (Scheltens et al., 1992). The 
hippocampus is involved in the consolidation process, which means that memories are solidi-
fied in long-term stores over weeks, months, and years. The CA1 region of the hippocampus 
is the origin of connections from the hippocampus to the neocortex that are important in the 
consolidation process of episodic memory (Gazzaniga, 2009). Typical for AD patients is a 
disturbance in these connections known as antrograde amnesia (Vanderploeg, Yuspeh & 
Schinka, 2001). Antrograde amnesia is an inability to store new information, leading to a par-
tial or complete inability to recall the recent past (Lezak, Howieson, Bigler & Tranel, 2012).  
In contrast, patients with VaD have problems with retrieving information (Vanderploeg et al., 
2001). Retrieval uses the stored information to create a conscious memory to produce an ac-
tion. The deficit in the retrieval process is caused by damaged connections between the hippo-
campus and other brain regions (Gazzaniga, 2009). Thus, patients with AD have consolidation 
deficits whereas patients with VaD have retrieval deficits.  
 
1.2 Memory Measurement Trials 
  Immediate recall, delayed recall and recognition trials are the most frequently used 
tasks to measure consolidation and retrieval deficits. Immediate recall is recall immediately 
after the presentation of the stimulus, whereas delayed recall is recall after a certain period of 
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time. Recognition is the capacity to identify an item as one that was recently encountered. 
There are two different underlying processes, immediate recall and delayed recall needs active 
brain processes and recognition needs a passive brain process. Thus, recognition tasks are 
easier in comparison to immediate and delayed recall tasks.  A meta-analysis of 47 studies 
showed delayed reproduction as the best measure for estimating the cognitive impairment of 
patients with AD (Bäckman, Jones, Berger, Laukka & Small, 2005). Furthermore, patients 
with AD had a negligible improvement in the learning curve with repeated measures (Burkart, 
Heun & Benkert, 1998; Bigler, Rosa, Schultz, Hall & Harris, 1989).  An important character-
istic of AD on memory tasks is the absence of improvement on recognition task (Dubois et al, 
2007), whereas the recognition performance in VaD patients is usually normal (Jonker, Slaets 
& Verhey, 2009).  
  A few studies have evaluated memory with the uses of immediate recall, delayed re-
call and recognition trials. Hong et al. (2013) have evaluated these trials between patients with 
AD and patients with subcortical ischemic vascular dementia (SIVD) based on the Seoul Ver-
bal Learning Test (SVLT) and the visual Rey Complex Figure Test (RCFT). Patients with AD 
and SIVD scored equally on the immediate recall trial based on the SVLT. They found that 
patients with SIVD scored significantly higher in comparison to patients with AD on the de-
layed recall trial and the recognition trials based on the SVLT. By contrast, there was no sig-
nificant difference found on those trials based on the RCFT. Graham et al. (2004) has also 
studied verbal and visual immediate recall, delayed recall and recognition of patients with AD 
and VaD based on the Logical memory subtest of the Wechsler memory scale and the “Doors 
and people test”. They also compared the patients with AD and VaD on these tasks. They 
found that patients with VaD perform significantly better on the verbal immediate recall trial 
and visual immediate recall trial in comparison to patients with AD based on the “Doors and 
people test”. Furthermore, they found that patients with VaD also perform significantly better 
on the verbal delayed recall trial based on the logical memory subtest and on the visual de-
layed recall trial based on the “Doors and people test”. Graham et al. (2004) used the short 
Recognition Memory Test (RMT; for words and faces) and the “Doors and people test” to 
measure visual and verbal recognition. They found that patients with VaD perform signifi-
cantly better in comparison to patients with AD on verbal recognition based on the “Doors 
and people test”. They found no significant difference in performance based on the visual 
recognition task. These results of the verbal recognition task are in accord with the results of 
Lafosse et al., (1997). They studied recognition between patients with AD and patients with 
VaD on a devised verbal recognition trial based on the list-learning subtest of the Memory 
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Assessment Scale (MAS). They found normal verbal recognition for patients with VaD, ver-
sus impaired verbal recognition for patients with AD. 
  The studies of Hong et al. (2014) and Graham et al. (2004) didn’t evaluated the com-
parison of the immediate recall trial with the delayed recall trial for patients with AD and pa-
tients with VaD. They also didn’t evaluate the comparison of the immediate recall trial with 
the recognition for those patients. Thus, the results described below are descriptive and based 
on mean scores. Hong et al. (2014) found that patients with AD scored approximately 10.7 
words lower on the delayed recall and patients with VaD scored approximately 9.4 words 
lower on the delayed recall trial in comparison to the immediate recall trial based on the 
SVLT. Patients with AD and patients with VaD scored both better on the recognition trial in 
comparison to the immediate recall trial based on the SVLT. Patients with AD scored on av-
erage 51.5 more words correct on the recognition trial and patients with VaD scored on aver-
age 59.3 more words correct on the recognition trial in comparison to the immediate recall 
trial. By contrast, the mean of the immediate recall and the delayed recall trials for both 
groups were almost equally based on the RCFT. Furthermore, patients with AD scored on 
average 60.6 more figure parts correct on the recognition task and patients with SIVD scored 
on average 64.1 more figure parts correct on the recognition task in comparison to the imme-
diate recall task. The findings of the study of Hong et al., (2014) were almost in line with the 
study of Graham et al. (2004), there were three differences. First, patients with AD scored 
almost equally on the immediate recall trial and on the recognition trial based on the visual 
“Doors and people test”. Second, patients with VaD scored almost equally on the immediate 
recall trial and on the recognition trial based on the verbal “Doors and people test”. Last, pa-
tients with VaD scored 4.5 photographs more correct on the immediate recall trial in compari-
son to the recognition trial based on the visual “Doors and people test”. Thus, this suggests 
that patients with AD improve on the verbal recognition trial and patients with VaD didn’t 
improve on the visual and the verbal recognition trial. 
  Overall, there are contradictory results based on the verbal immediate recall trial, the 
visual immediate recall trial and the delayed recall trial. However, as expected, all the studies 
concluded that patients with VaD perform relatively better in comparison to patients with AD 
based on the verbal delayed recall trial, the verbal recognition trial and the visual recognition 
trial. Furthermore, as expected, almost all studies suggest that patients with AD and VaD 
scored relatively better on the immediate recall trial in comparison to the delayed recall trial. 
By contrast, there are contradictory results between the immediate recall trial and the recogni-
tion trial. That patients with VaD improved more could be explained by the typical antrograde 
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amnesia in patients with AD. 
 
1.3 Visual and Verbal Recognition Trial 
   The studies of Hong et al. (2013), Graham et al. (2004) and Lafosse et al., (1997) have 
only evaluated a difference between patients with AD and patients with VaD on a verbal and 
a visual recognition task separately. These studies have not evaluated a comparison of a ver-
bal recognition task and a visual recognition task for each patient group. An example of a test 
with a verbal recognition trial is the 15 word task (15WT). The 15WT may result in floor ef-
fects to patients with amnestic mild cognitive impairment (aMCI) or AD. The visual VAT 
recognition task has not been studied in comparison with a verbal 15WT recognition task; the 
usefulness of this kind of visual recognition still awaits evaluation.  
  The Visual Association Test (VAT; Lindeboom & Schmand, 2003) and the Dutch ver-
sion of the Rey Auditory Verbal Learning Test the 15WT (Saan & Deelman, 1986) are exam-
ples of memory tests. The VAT is designed to detect visual anterograde amnesia (Lindeboom 
& Schmand, 2003), whereas the 15 WT (Saan & Deelman, 1986) is designed to detect verbal 
antrograde amnesia. The VAT has only two immediate recall trials and sometimes an infor-
mal recognition trial was used, but the informal recognition is not standardized. Whereas the 
15WT includes five immediate recall trials, a delayed recall trial and a recognition trial. Mey-
er et al. (in preparation) have developed a new version of the VAT. This VAT includes a new 
parallel version, version C en D. They developed new cues and targets for the new parallel 
version. These new parallel versions include a delayed recall trial and recognition trial. The 
recognition trial of the 15WT exists of 30 nouns, and the subject was asked to say if the word 
occurs in the learned phase of the immediate recall trial. By contrast, in the recognition trial of 
the VAT, the subject learned six associations between a cue and target. In the recognition tri-
al, the subject was shown a cue and four targets. The subject was asked to say which of the 
four targets belonged to the cue. It’s known that patients with AD score lower on the immedi-
ate recall of the VAT than patients with VaD (Lindeboom,, Schmand, Tulner, Walstra & 
Jonker, 2002), but it’s unknown if AD patients score lower on the recognition trials of the 
VAT as well. Thus, the recognition trial of the VAT and it’s comparison with a verbal recog-
nition trial for AD and VaD patients needs an evaluation. 
 
1.4 This Study 
  The aim of this cross-sectional study was to determine if there is a discriminative va-
lidity possible between patients with AD on one hand and patients with VaD on the other 
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hand based on the VAT recognition trial. The group of patients with VaD was too small, for 
this reason we joined the patients with AD and the patients with aMCI. We also joined the 
patients with VaD and the patients with VCI. Furthermore, we have evaluated in an explorato-
ry manner all research questions between the severities of the dementia type’s and for the pa-
tients with aMCI and patients with VCI. Patients with aMCI or AD have consolidation prob-
lems, so they can’t recognize what they have learned. By contrast, patients with VCI or VaD 
only have retrieval deficits. Therefore, it’s expected that patients with aMCI or AD score rela-
tively lower on the VAT recognition trial in comparison to the patients with VCI or VaD. In 
addition, it’s expected that aMCI patients score relatively more items correct on the VAT 
recognition trial in comparison to patients with AD and patients with VCI score relatively 
more items correct on the VAT recognition trial in comparison to patients with VaD.  
  Second, we have evaluated in an exploratory manner the score difference between the 
VAT immediate recall trial one and the VAT immediate recall trial two in comparison to the 
score difference between the VAT immediate recall trial two and the VAT delayed recall trial 
for all groups. We also evaluated the score difference between the VAT immediate recall trial 
one and the VAT immediate recall trial two in comparison to the score difference between the 
VAT immediate recall trial two and the VAT recognition trial for all groups. Thereby, we 
have evaluated if there is a difference in those two scores between the groups and between the 
severities of dementias. Immediate recall and delayed recall are more difficult than recogni-
tion, because immediate recall and delayed recall were active processes whereas recognition 
is a passive process. Immediate recall is easier in comparison to delayed recall, because de-
layed recall calls for longer withhold of information. A characteristic of patients with AD is 
the absence of improvement on the recognition task (Dubois et al, 2007), whereas the recogni-
tion performance of patients with VaD is usually normal (Jonker, Slaets & Verhey, 2009). 
Therefore, it’s expected that the score difference between the VAT immediate recall trial and 
the VAT delayed recall is lower in comparison to the score difference between the VAT im-
mediate recall trial one and the VAT immediate recall trial two for all groups. It’s also ex-
pected that the score difference between the VAT immediate recall trial and the VAT recogni-
tion trial is higher in comparison to the score difference between the VAT immediate recall 
trial one and the VAT immediate recall trial two for all groups. In addition, it’s expected (1) 
that patients with VaD show more improvement based on the VAT recognition trial than pa-
tients with AD, (2) patients with aMCI show more improvement based on the VAT recogni-
tion trial than patients with AD and (3) patients with VCI improve more than patients with 
VaD based on the VAT recognition trial.  
10 
 
  Last, we have evaluated in an exploratory manner the difference in performance on a 
verbal recognition task (15WT) in comparison to a visual recognition task (VAT) for patients 
with aMCI or AD and patients with VCI or VaD. The previous studies found only a difference 
on verbal recognition task in comparison to the visual recognition task between patients with 
AD and patients with VaD. This has never been studied using the VAT recognition trial, be-
cause the VAT recognition trial is developed recently. Furthermore, most of the current tests 
may result in floor effects to patients with aMCI or AD (Kessels et al., 2009; Petersen et al., 
1999; Ricci, Graef et al., 2012). Thus, it is studied using the VAT recognition trial. It’s ex-
pected that patients with aMCI or AD and patients with VCI or VaD score relatively more 
items correct on the visual recognition task of the VAT in comparison with the verbal recog-
nition task of the 15WT. 
 
2. METHODS 
2.1 Participants 
  The study patients were geriatric outpatients and nursing home day care patients (N = 
55). The outpatients were recruited from the Medical Center Alkmaar (MCA) geriatric 
memory clinic and  nursing home day care facilities (MagentaZorg, SHDH, Zorgbalans, 
Zorgcirkel en Topaz). Patients were eligible for inclusion if they were 65 years or older, and 
had intact hearing and vision. Patients were also eligible for inclusion if they met the consen-
sus diagnostic criteria for MCI, AD, VCI and VaD (Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition, Text Revision [DSM-IV-TR]; American Psychiatric Asso-
ciation, 2000; Dubois et al., 2007; Petersen et al., 2001; Román et al., 1993; Steele, Richard-
son & Olszewski, 1964). These diagnoses were given in a multidisciplinary consultation. Fi-
nally, patients were eligible for inclusion if they had a score of less than 10/12 on the VAT 
immediate recall trial one and two, because when they showed a normal immediate recall 
score than they can learn normally an thus recognize normally. Patients were excluded from 
the study if they had severe traumatic brain injury, brain tumour, epilepsy, multiple sclerosis, 
Parkinson’s disease, psychiatric disorder, delirium, or treatment in the past for addiction to 
alcohol or drugs. Finally, patients were excluded if they had a mixed diagnosis with another 
type of dementia. 
   The total sample contained 41 geriatric outpatients and 14 nursing home day care pa-
tients. Thereof, were 19 patients with aMCI, 25 patients with AD, 6 patients with VCI and 5 
patients with VaD. We joined the patients with aMCI and the patients with AD together and 
the patients with VCI and the patients with VaD together, because of the low number of pa-
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tients with VCI and patient with VaD. Thus, the group with aMCI or AD consisted of 44 pa-
tients and he group with VCI or VaD consisted of 11 patients. 
 
2.2 Measurement 
  The Visual Association Test (VAT; Lindeboom & Schmand, 2003), the two new par-
allel version of the Visual Association Test (VAT; Meyer et al., in preparation) and the Dutch 
version of the RAVLT (15WT; Saan & Deelman, 1986) were used as measurements. The 
VAT is designed to detect visual antrograde amnesia. Versions A, B, C and D of the VAT 
were used. There is a short (6 items) and a long item version (12 items). The short version is 
to test older adults (65+). For this study the six item version was used. The six items are pic-
tures, exciting a cue and a target. For example a monkey (cue) holding an umbrella (target). 
At first, the six consecutive cues that have to be named are presented (step one). The next 
pictures are an interaction between the cue and the corresponding target. The subjects were 
asked to name the target (step two).  The six cues were shown again, and the subject was 
asked to recall the associated target (step tree; immediate recall trial). The final step of version 
A en B was to repeat step two and three. The total score of the immediate recall trial is the 
two repeated measures together with a maximum score of 12. The internal consistency 
(Cronbach’s alpha) is 0.86 and the test-retest reliability is 0.81. The parallel version reliability 
(Spearman rank correlation) is 0.84 (Lindeboom & Schmand, 2003). Meyer et al. (in prepara-
tion) has developed version C and D. The new versions have immediate recall trial as well as 
version A en B, but with new cues and targets. They have also added a delayed recall trial and 
a recognition trial. In the delayed recall trial, the six consecutive cues were shown. The sub-
jects were asked to name the missing target (step four). In the recognition trial, four pictures 
were shown with the cue picture above. The four target pictures include two semantically re-
lated pictures to the cue and one semantically related picture tot the target. The subject was 
asked to designate the target (step 5). The recognition is impaired if 4 or less than 4/6 items 
were correct. The parallel versions correlated substantially (r = 0.91) with the original VAT 
(Lindeboom & Schmand, 2003). 
  The 15WT is designed to detect verbal antrograde amnesia. The subject hears a list of 
15 nouns five times. After each presentation the subject was asked to recall as many words as 
possible (immediately recall trial; step one). The total score (maximum 75) is the sum of all 
the five recall trials. The immediately recall trial was followed by a delayed recall trial, where 
the subject was asked to recall as many words without presenting the word list (step two). 
Each condition consisted of 15 words. The last step is the recognition trial (step three).  The 
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subject heard a list of 30 nouns. The subject was asked to say ‘yes’ when the word was in the 
learned list and say ‘no’ when the word wasn’t in the learned list. The recognition was im-
paired if 26 or less than 26/30 items were correct. The reliability of this test is good. The in-
ternal consistency (alpha Cronbach's) is 0.91 to 0.93 and test-retest reliability is 0.80 to 0.83 
(Saan & Deelman, 1986, cited in Bouma, Mulder, Lindeboom & Schmand, 2012). 
   
2.3 Procedure 
  The subjects were investigated with a screening questionnaire to determine whether 
patients met the inclusion and exclusion criteria. Prior to the study they were asked to read 
and sign the form 'informed consent patient'.  
  The data was collected by Meyer, Spaan, Boelaarts, Schmand & Jonghe (in prepara-
tion). The patients received the following investigations: neuropsychological assessment, clin-
ical geriatric assessment, laboratory and imaging investigation and if necessary, a psychiatric 
assessment. The partners or care-givers conducted the neuropsychological tests simultaneous-
ly with the ambulatory geriatric patients. The neuropsychological assessment included the 
following tests: the VAT, the Groninger Intelligence Task (subtask wordlist, animals and job), 
Name animal plate and show animals plate task, the 15WT,  the Stroop Color-Word Task 
(subtask card I; SKWT-Kaart I), the Amsterdamse Dementia-Screening task  (subtask copy-
ing; ADS6-copying), the VAT, Cognitive Screening Task-20 (CST-20) and the Amsterdamse 
Dementia-Screening task (subtask Orientation; ADS6-Orientation). The 15WT wasn’t admin-
istered to the nursing home patients because of their limited mental capacity. Clinicians and 
neuropsychologists were blinded to the second VAT scores. Following this, the diagnosis of 
the patient was given in a multidisciplinary consultation. This study is a part of the neuropsy-
chological assessment. 
  The main focus of this study was the VAT. The patients were randomly distributed 
over the four conditions (A-C, C-A, B-D, D-B) of the VAT. The conditions were counterbal-
anced to check for learning effect, priming, fatigue, or boredom effects. At a later moment, 
two new conditions were added (C-D and D-C). There was a time interval of at least 30 
minutes between the first and the second test administration of the VAT (Lindeboom & 
Schmand, 2003). The VAT is administered two times because the old version of the VAT is 
used for the diagnosis of the patient and the second VAT administration was used for research 
purpose. By the first administration, only the VAT immediate recall was administered. By the 
second administration, immediate recall, delayed recall and recognition were administrated. 
There was a 25 minute time interval between the learned information and the VAT delayed 
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recall trial. Finally, the delayed recall trial was immediately followed by the recognition trial.   
 
2.4 Statistical Analyses  
   Study data were analyzed, using SPSS-21 statistical software (SPSS Inc., Chicago, 
IL). We performed Mann-Whitney U-tests and the Chi-square test for inter-group compari-
sons of demographic and cognitive scores. The non-parametric Mann-Whitney U-test and the 
Wilcoxon signed-ranks test were used to analyze data.  
  Comparisons of the groups (patients with aMCI or AD – patients with VCI or VaD), 
subgroups (AD – VaD and aMCI – VCI) and between the severity of the dementia types 
(aMCI– AD and VCI –  VaD) on the VAT recognition trial and the other VAT trials (immedi-
ate recall trial one, immediate recall trial two and the delayed recall trial) were made using the 
Mann-Whitney U-test. The groups were used as the independent variables and the VAT 
recognition trial and the other VAT trials (immediate recall trial one, immediate recall trial 
two and the delayed recall trial) were used as dependent variables. 
  Comparisons of the scores of the trials for each group (patients aMCI or AD, patients 
with VCI or VaD, aMCI, AD , VCI and VaD) were made using Wilcoxon Singed Ranks Test. 
The following comparisons were made for each group: VAT immediate recall trial one – 
VAT immediate recall trial two, VAT immediate recall trial two – VAT delayed recall trial 
and VAT immediate recall trial two – VAT recognition trial. Following this, comparison of 
the scores is made using the Mann-Whitney U-test. Before the comparison, the following new 
variables were calculated: ∆Im2Im1 = immediate recall trial two – immediate recall trial one; 
∆DelIm2 = delayed recall trial – immediate recall trial two and ∆RecIm2 = recognition trial – 
immediate recall trial two. There were comparisons made between the groups, subgroups and 
between the severities of the dementia types as described above. The groups were used as the 
independent variables and the three difference variables were used as dependent variables. 
  Comparisons of the score difference between the VAT immediate recall trial one and 
the VAT immediate recall trial two with the score difference between the VAT immediate 
recall trial two and the VAT delayed recall trial were made using the Wilcoxon Singed Ranks 
Test. The same statistical analysis was used for the comparison of the score difference be-
tween the VAT immediate recall trial one and the VAT immediate recall trial two with the 
score difference between the VAT immediate recall trial two and the VAT recognition trial. 
The followed new variables were calculated: ∆DelIm2. Im2Im1= ∆DelIm2 – ∆Im2Im1 and 
∆RecIm2.Im2Im1 = ∆RecIm2 – ∆Im2Im1. The following comparisons were made using the 
Wilcoxon Singed Ranks Test: ∆Im2Im1 –∆DelIm2 and ∆Im2Im1 –∆RecIm2. Those compari-
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sons were made for all the groups. Following this, the comparison of the improvement for 
each group, subgroup and between the severities of the dementia types were made using the 
Mann-Withney U-test..  
 Comparisons of performance on the verbal recognition (15WT) trial and the visual 
recognition (VAT) trial for all the groups were made using the Wilcoxon Singed Ranks Test. 
Before the comparisons, two new variables were calculated because of an unequal number of 
items. The performance of the 15WT was measured as follows: (correct items/30) x 100. The 
performance of the VAT was measured as follows: (correct items/6) x 100. 
 Statistical tests were deemed significant if the two sided p value was less than 0.05. 
 
3. RESULTS 
  This study sample consists of geriatric outpatients and nursing home day care patients 
from 65 and older.  A total of 346 patients were screened for eligibility to participate in the 
study. Thereof, 228 patients didn’t met inclusion criteria. The VAT recognition trial was not 
administered to a total of 56 out of the 346 patients. Of the remaining 62 patients, 7 had more 
than 10 out of the 12 items correct on the VAT immediate recall trial one and the VAT imme-
diate recall trial two. The comparison for those patients with the VAT recognition trial is un-
interesting because those patients already showed normal learning on the VAT immediate 
recall trial one and trial two. The 15WT was not administered for a total of 15 out of the 55 
patients. Finally, 55 patients were included for the first and the second hypothesis and 40 pa-
tients were included for the third hypothesis in this study. 
  
3.1 Patient Characteristics  
  Patient characteristics are presented in table 1. The patients with aMCI and patients 
with AD were taken together and patients with VCI and patients with VaD were taken togeth-
er, because the patients with VCI and patients with VaD both had a low number of partici-
pants. These analyses might be biased, because patients with VCI or aMCI were low dement-
ed and patients with AD or VaD were more demented. Therefore, we also evaluated the 
groups separately.  
  We evaluated if the groups were equal on age, gender, education and MMSE.  We 
evaluated the MMSE to check if the patients with AD or VaD were actually more demented 
in comparison to the patients with aMCI or VCI. Patients with aMCI or AD in comparison to 
the patients with VCI or VaD were both mildly demented based on the MMSE, but the pa-
15 
 
tients with aMCI or AD scored significantly (on average 4.1) lower in comparison to the pa-
tients with VCI or VaD (U = 180, p < .05). Based on the subgroups, patients with VCI were 
higher educated in comparison to the patients with aMCI (U = 26.5, p < .05). We found also 
that patients with aMCI were mildly demented, whereas the patients with VCI were not de-
mented based on the MMSE score (U = 8, p < .05). As expected, the patients with AD were 
more demented in comparison to the patients with aMCI. The patients with AD were moder-
ate demented, whereas the patients with aMCI were mildly demented. (U = 131.5, p < .05).  
Last, the patients with VaD were mildly demented whereas the patients with VCI were not 
demented (U = 1, p < .05).  
 
3.2 Comparisons of Performance of the Groups Based on the VAT Trials 
  The results of the groups based on the VAT trials are presented in Table 2. The results 
below must be interpreted with caution, because we did multiple Mann-Whitney u-Tests. This 
means high chances to get Type-1 errors. 
 
3.2.1 VAT Recognition Trial 
  Patients with aMCI or AD on one hand and the patients with VCI or VaD on the other 
hand did equally well on the VAT recognition trial (see Table 2; U = 194.00, p = .29). None-
theless, we separated the patients with aMCI from the patients with VCI, and compared the 
groups. They still did equally well on the VAT recognition trial (U = 50.5, p = .58). The same 
was found if we took the patients with AD and the patients with VaD separately (U = 49, p = 
.45). All the groups, except the patients with aMCI and the patients with VCI had an impaired 
recognition based on the VAT recognition trial (recognition < 5/6 items correct). However, 
we found a possible differentiation of the severity of the dementia types based on the VAT 
recognition trial. Patients with aMCI scored 3.0 items more correct in comparison to the pa-
Table 1. Characteristics of the groups and subgroups.  
 aMCI+AD VCI+VaD MCIa VCI AD VaD 
 (n = 44) (n = 11) (n = 19) (n = 6) (n = 25) (n = 5) 
Characteristic M (SD) 
Age 79.0 (5.7) 77.4 (7.4) 78.4 (6.6) 77.3 (4.4) 79.5 (5.1) 77.4 (10.7) 
1Education 4.4 (1.6) 4.8 (1.5) 4.3(1.4) 5.5 (1.4) 4.4 (1.7) 4.0 (1.2) 
MMSE 20.8 (6.0) 24.9 (5.0) 23.6 (3.4) 27.7 (.52) 18.8 (6.8) 21.6 (6.1) 
Male/female 18/26 6/5 5/14 4/2 13/12 2/3 
1Education code according to Verhage (1964): 1. less than primary school/not finished; 2. primary school finished; 3. Primary school finished 
+ further education less than 2 years; 4. Lower than MULO/MAVO-level, b.v. LTS, LEAO, LHNO; 5. MULO/MAVO/MEAO diploma; 6. 
HAVO/VWO/HEAO/HBS/HBO diploma; 7. VWO/universitair diploma 
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tients with AD (U = 70, p = .00). By contrast, the patients with VCI and the patients with VaD 
did equally well on the VAT recognition trial (U = 4.5, p = .05). 
  In contrast to our expectations, we found that there’s no differentiation possible be-
tween the types of dementias based on the VAT recognition trial. However, we found a possi-
ble differentiation based on the VAT recognition trial between the severities of dementia 
types, especially between the patients with aMCI and the patients with AD. 
 
3.2.2 VAT Immediate and Delayed Recall Trials 
  Patients with VCI or VaD scored 1.6 correct items more on the VAT immediate recall 
trial two (U = 144.5, p = .03) and they scored 1.8 correct items more on the delayed recall 
trial (U = 129.0, p = .01) in comparison to the patients with aMCI or AD (see Table 2). There 
was no significant difference found between patients with VCI or VaD and patients with 
aMCI or AD based on the VAT immediate recall trial one (U = 193, p = .29). When we sepa-
rated the patients with aMCI from the AD patients and the patients with VCI from the patients 
with VaD, we found that patients with VCI scored 1.8 correct items more on the VAT delayed 
recall trial in comparison to the patients with aMCI (U = 24.5,  p = .03). There was no signifi-
cant difference found between patients with VCI and patients with aMCI based on the VAT 
immediate recall trial one (U = 56.5, p = .98) and the VAT immediate recall trial two (U = 
28.5, p = .06). There was also no significant difference found between patients with VaD and 
patients with AD based on the VAT immediate recall trial one (U = 48, p = .38), VAT imme-
diate recall trial two (U = 42.5, p = .24) and the VAT delayed recall trial (U = 38, p = .14). 
However, we found a possible differentiation of the severities of the dementia types based on 
the VAT trials. We found that patients with aMCI scored on average 1.7 correct items more 
on the VAT immediate recall trial two (U = 134.5, p = .01) in comparison to patients with 
AD. Furthermore, they scored on average 1.5 correct items more on the delayed recall trial (U 
= 138, p = .01). There was no significant difference found between those patients based on the 
VAT immediate recall trial one (U = 159, p = .05). In contrast, we found no significant differ-
ence between the patients with VCI and the patients with VaD based on the VAT immediate 
recall trial one (U = 15, p = 1.00), VAT immediate recall trial two (U = 7.5, p = .16) and the 
VAT delayed recall trial (U = 7, p = .14). 
  Thus, as expected, we found a possible differentiation for the patients with aMCI or 
AD on one hand and patients VCI or VaD on the other hand based on the VAT immediate 
recall trial two and the VAT delayed recall trial. Last, the same is found for the patients with 
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aMCI and the patients with AD. 
 
Table 2. Performances on the VAT trials 
 aMCI+AD VCI+VaD p aMCI VCI p AD VaD p 
Im1 1.8 (1.8) 2.4 (1.5) .286 2.4 (1.8) 2.5 (1.0) .974 1.3 (1.6) 2.2 (2.0) .384 
Im2 2.5 (2.2) 4.1 (2.1) .037* 3.5 (1.8) 5.0 (1.1) .063 1.8 (2.2) 3.0 (2.5) .244 
Del 2.1 (2.1) 3.9 (1.9) .014* 3.0 (1.9) 4.8 (.98) .033* 1.5 (2.1) 2.8 (2.3) .138 
Rec 3.9 (2.3) 4.8 (2.0) .287 5.6 (.84) 5.8 (.41) .580 2.6 (2.3) 3.6 (2.5) .445 
Values are mean (SD). Im 1 = Immediate recall trial one; Im 2 = Immediate recall trial two; Del = delayed recall; Rec = Recognition 
* p < .05 
 
3.3 Comparison of the VAT Trials  
  The results of the differences between the VAT trials for each groups and between the 
groups are presented in Table 3 and the comparison of ∆om2Om1 with ∆DelOm2 and 
∆RecOm2 for each group and between the groups are presented in Table 4. The results below 
must also be interpreted with caution, because we did multiple Mann-Whitney u-Tests. This 
means high chances to get Type-1 errors. 
 
3.3.1 Comparison of the VAT Trials with the VAT Immediate Recall Trial Two 
  Patients with aMCI or AD (Z = -3.71, p =.00 ), patients with VCI or VaD (Z = -2.57, 
p = .01), patients with aMCI (Z = -2.76, p =.01), patients with AD (Z = -2.65, p = .01) and 
patients with VCI (Z = -2.23, p = .03) except the patients with VaD (Z = -1.13, p = .26) im-
proved significantly from VAT immediate recall trial one to the VAT immediate recall trial 
two (see Table 3).  
  After this improvement, we expected deterioration from the VAT immediate recall 
trial two to the VAT delayed recall trial. But this was only the case for patients with aMCI or 
AD (Z = -2.80, p = .01) and for patients with aMCI (Z = -4.78, p = .00).  
  Conversely, patients with aMCI or AD (Z = -4.78, p = .00), patients with VCI or VaD 
(Z = -2.07, p = .04), patients with aMCI (Z = -3.65, p = .00), patients with AD (Z = -3.09, p 
= .00) except the patients with VCI (Z = -1.63, p = .10) and the patients with VaD (Z = -1.34, 
p = .18) significantly improved from the VAT immediate recall trial two to the VAT recogni-
tion trial.  
  However, we found significant improvement difference between the groups based on 
the severity of the dementias. Patients with aMCI improved significantly with .68 items more 
correct from the VAT immediate recall trial one to the VAT immediate recall trial two in 
comparison to patients with AD (U = 158, p = .048). By contrast, we found no significant 
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deterioration group difference from the VAT immediate recall trial two to the delayed recall 
trial for patient with aMCI in comparison to patients with AD (U = 202.5, p = .33).  Further-
more, we found also that aMCI patients with 1.34 correct items more improved from the VAT 
immediate recall trial two to the VAT recognition trial (U = 110, p = .00). By contrast, pa-
tients with VCI and patients with VaD perform equally from the VAT immediate recall trial 
one to the VAT immediate recall trial two (U = 5.5, p = .08), from the VAT immediate recall 
trial two to the VAT delayed recall trial (U = 14.5, p = .89) and from the VAT immediate re-
call trial two to the VAT recognition trial (U = 13, p = .69). 
  As expected, all patients except the patients with VAD significantly improved from 
the VAT immediate recall trial one to the VAT immediate recall trial two. We only found that 
patients with aMCI or AD and patients with aMCI deteriorate from the VAT immediate recall 
trial two to the VAT delayed recall trial. We found group differences based on the severity of 
the dementia types. Patients with aMCI improve significantly more from the VAT immediate 
recall trial one to the VAT immediate recall trial two and from the VAT immediate recall trial 
two to the VAT recognition trial in comparison to patients with AD. 
 
Table 3. Difference between the VAT trials for each groups and between the groups 
 aMCI+AD VCI+VaD p* aMCI VCI p* AD VaD p* 
Om2-Om1 .80 (1.2)* 1.7 (1.6)* .052 1.2 (1.4)* 2.5 (1.4)* .080 .52 (.87)* .80 (1.5) .706 
Del-Om2 -.41 (1.1)* -.18 (.41) .321 -.53 (1.5) -.17 (.41) .400 -.32 (.56)* -.20 (.45) .787 
Rec-Om2 1.3 (1.3)* .73 (.91)* .179 2.1 (1.4)* .83 (.98) .069 .76 (.97)* .60 (.89) .746 
Values are mean (SD). Im 1 = Immediate recall trial one; Im 2 = Immediate recall trial two; Del = delayed recall; Rec = 
Recognition 
* p < .05 
 
3.3.2 Comparison of the VAT Immediate Recall Trials with the VAT Delayed Recall and 
Recognition Trial 
  We have also evaluated the score difference between the VAT immediate recall trial 
one and the VAT immediate recall trial two in comparison to the score difference between the 
VAT immediate recall trial two and the VAT delayed recall trial for all groups. Patients with 
aMCI or AD (Z = -3.73, p =.00), patients with VCI or VaD (Z = -2.57, p = .01), patients with 
aMCI (Z = -2.51, p =.01), patients with AD (Z = -2.86, p = .01) and patients with VCI (Z = -
2.23, p = .03) except the patients with VaD (Z = -1.13, p = .26) significantly deteriorated 
from the VAT immediate recall trial two to the VAT delayed recall trial in comparison to the 
VAT immediate recall one to the VAT immediate recall trial two (see Table 4). There was no 
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significant deterioration found between the patients with aMCI or AD and patients with VCI 
or VaD, between the patients with aMCI and VCI and between the patients with AD and 
VaD. 
 Therefore, we have evaluated the score difference between the VAT immediate recall 
trial one and the VAT immediate recall trial two in comparison to the score difference be-
tween the VAT immediate recall trial two and the VAT recognition trial for all groups. Pa-
tients with aMCI or AD (Z = -1.62, p =.11), patients with VCI or VaD (Z = -1.41, p = .16), 
patients with aMCI (Z = -1.64, p =.10), patients with AD (Z = -.74, p = .46), patients with 
VCI (Z = -1.63, p = .10) and patients with VaD (Z = -1.13, p = .26) improve equally from the 
VAT immediate recall trial two to the VAT recognition trial in comparison to the VAT im-
mediate recall one to the VAT immediate recall trial two. Patients with aMCI or AD im-
proved more from the VAT immediate recall trial two to the VAT recognition trial in compar-
ison to the improvement from the VAT immediate recall trial one to the VAT immediate re-
call trial two in comparison to patients with VCI or VaD (U = 146.5, p = .04). The same was 
found for patients with aMCI and patients with VCI, only patients with aMCI improve from 
the VAT immediate recall two to the VAT recognition (U = 24.5, p = .04). 
  Overall, as expected, all patient groups except patients with VaD deteriorate from the 
VAT immediate recall trial two to the VAT delayed recall trial in comparison to the VAT 
immediate recall trials (trial one and two). Furthermore, in contrast to our expectations, all the 
patient groups improve equally from the VAT immediate recall trial two to the VAT recogni-
tion trial in comparison to the VAT immediate recall trials (trial one and two). We found also 
that patients with aMCI or AD and patients with aMCI improved more from the VAT imme-
diate recall trial two to the VAT recognition trial in comparison to the VAT immediate recall 
trials (trial one and two). 
 
 
3.4 Comparison of the Visual (VAT) and the Verbal (15WT) Recognition Trial 
  The results on the visual (VAT) and the verbal (15WT) recognition trial of each group 
are presented in Table 5. Patients with aMCI or AD performed 10.8% better on the visual 
Table 4. Comparison of ∆om2Om1 with ∆DelOm2 and ∆RecOm2 for each group and between the groups. 
 aMCI+AD VCI+VaD p* aMCI VCI p* AD VaD p* 
∆DelOm2 -1.2 (2.1)* -1.9 (1.8)* .231 -1.7 (2.8)* -2.7 (1.5)* .366 -.84 (1.2)* -1.0 (1.9) .914 
∆RecOm2 .52 (1.9) -1.0 (2.2) .042* .90 (2.4) -1.7 (2.2) .036* .24 (1.5) -.20 (2.2) .516 
Values are mean (SD). Im1 = Immediate recall trial one; Im 2 = Immediate recall trial two; Del = delayed recall; Rec = Recognition 
* p < .05 
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VAT recognition trial in comparison to the verbal 15WT recognition trial (Z = -2.15, p = .03) 
By contrast, patients with VCI or VaD  showed no significant difference on the visual VAT 
recognition trial in comparison to the verbal 15WT recognition trial (Z = -.71, p = .48). Pa-
tients with aMCI or AD and patients with VCI or VaD both showed impaired recognition only 
on the 15WT recognition trial.  
   When we took the groups separately, aMCI patients performed 22.6% better on the 
visual VAT recognition trial in comparison to the verbal 15WT recognition trial (Z = -3.29, p 
= .00). By contrast, there were no significant difference found for patients with VCI (Z = -
1.37, p = .17), patients with AD (Z = -.83, p = .41) and patients with VaD (Z = -.54, p = .59). 
Patients with AD and patients with VaD showed an impaired recognition on the visual VAT 
recognition trial and the verbal 15WT recognition trial. It’s remarkable that patients with 
aMCI and patients with VCI showed impaired recognition only on the verbal 15WT recogni-
tion trial. 
  In the end, as expected, we may conclude that only patients with aMCI or AD and 
patients with aMCI scored relatively higher on the visual VAT recognition trial in comparison 
to the verbal 15WT recognition trial.  
 
Table 5. Performance of the recognition of the VAT and the recognition of the 15WT  
  Recognition VAT Recognition 15WT   
 N M (SD) % correct1 M (SD) % correct2 %  correct difference p value* 
aMCI + AD 31 4.9 (1.7) 81.2% 21.1 (3.1) 70.4% 10.8%  .032* 
VCI + VaD 9 5.3 (1.3) 88.9% 25.8 (3.6) 85.9% 3% .476 
aMCI 19 5.6 (.84) 93.0% 21.1 (2.8) 70.4% 22.6% .001* 
VCI 6 5.8 (.41) 97.2% 26.0 (4.3) 86.7% 10.5% .172 
AD 12 3.8 (2.1) 62.5% 21.2 (3.6) 70.6% 8.1% .410 
VaD 3 4.3 (2.1) 72.2% 25.3 (2.1) 84.4% 12.2% .593 
1 ((M correct VAT recognition / 6) x 100%); 2((M correct 15WT recognition / 30) x 100%)  
*  p < .05  
 
4. DISCUSSION 
  The main goal of this study was to attempt to find a discriminative validity between 
patients with aMCI or AD and patients with VCI or VaD based on the VAT recognition trial. 
The new parallel versions of the VAT were developed because most of the current tests may 
result in floor effects to patients with amnestic mild cognitive impairment (aMCI) or AD 
(Kessels et al., 2009; Petersen et al., 1999; Ricci et al., 2012). Thus, there has no study been 
done to compare patients with aMCI or AD with patients with VCI or VaD. Furthermore, we 
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have evaluated in an exploratory manner the score difference of the VAT immediate recall 
trial one to the VAT immediate recall trial two in comparison to the score difference of the 
VAT immediate recall trial two to the VAT delayed recall trial and the score difference of the 
VAT immediate recall trial to the VAT recognition trial for each group and between the 
groups. Last, we have also evaluated in an exploratory manner the visual (VAT) recognition 
trial in comparison with a verbal (15WT) recognition trial. The VAT recognition trial is new 
developed. Thus, there’s no study done with the visual VAT recognition trial in comparison to 
the verbal 15WT recognition trial. The results of this study both negate and support some of 
the hypotheses. 
 
4.1 Findings  
  It was predicted that patients with VCI or VaD scored more items correct on the VAT 
recognition trial in comparison to the patients with aMCI or AD, but this turned out not to be 
the case, they performed equally well. The same is found if we separate the groups. This re-
sult could be due to the low number of patients with VCI or VaD, and thus the unequal 
groups. By contrast, our results suggested there only is a discriminative validity of the severi-
ty of the dementias based on the VAT recognition trial, especially between patients with 
aMCI and patients with AD. But, this result is obvious because patients with AD are more 
demented and therefore they show more impaired recognition. The result of our study is the 
same as the result of the study of Hong et al. (2013) and Graham et al., (2004). Conversely, 
our study is not supported by the theory. The theory suggests that patients with AD have con-
solidation deficits and patients with VaD have retrieval deficits. Thus, it seems to be that pa-
tients with AD score relatively lower on a recognition trial in comparison to patients with 
VaD (Lafosse et al., 1997). 
  It was expected that the score difference between the VAT immediate recall trial and 
the VAT delayed recall is lower in comparison to the score difference between the VAT im-
mediate recall trial one and the VAT immediate recall trial two for all groups. It’s also ex-
pected that the score difference between the VAT immediate recall trial and the VAT recogni-
tion trial is higher in comparison to the difference score between the VAT immediate recall 
trial one and the VAT immediate recall trial two for all groups. In addition, it’s expected that 
patients with VaD show more improvement on the VAT recognition trial than patients with 
AD. And patients with aMCI show more improvement on the VAT recognition trial than pa-
tients with AD and patients with VCI improve more than patients with VaD on the VAT 
recognition trial. The study of Hong et al. (2013) based on the visual RCFT did support our 
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findings with regard to the lower score of the VAT delayed recall trial in comparison to the 
VAT immediate recall for patients with AD and for patients with VaD. But, the results based 
on the better score on the RCFT recognition trial in comparison to the RCFT immediate recall 
trial for patients with AD and patients with VaD are not in line with our results. We found the 
same score difference between the VAT immediate recall trial two and the VAT recognition 
trial in comparison to the VAT immediate recall trial one to the VAT immediate recall trial 
two. By contrast, our results are in accord with the results of the study of Graham et al. (2004) 
with regard to patients with AD that they deteriorate from the immediate recall trial to the 
delayed recall trial. But these results are interpreted mean scores of the trials. There were no 
studies found were they did a statistical analysis based on the comparison of the immediate 
recall trials with the delayed recall trial and with the recognition trial. 
   Last, it was predicted that patients with aMCI or AD and patients with VCI or VaD 
scored relatively better on the visual VAT recognition trial in comparison to the verbal 15WT 
recognition trial. This is only the case for patients with aMCI or AD and for aMCI patients 
separately. The previous studies focus only on the trials between a verbal or a visual task for 
patients with AD and patients with VaD. We found no study that compares a visual task with 
a verbal task for patients with AD and patients with VaD. But it is well known that a verbal 
task is more difficult in comparison to a visual task. 
 
4.2 Limitations and Strengths 
  The current study had several limitations. First, in this study there was a low number 
of patients with VCI and patients with VaD. This may be explained by the prevalence of each 
diagnosis. The prevalence for patients withVaD is 2.2-16.3%, whereas the prevalence for pa-
tients with AD 50-75% is (Leys, Pasquier & Parnetti, 1998). By contrast, the study of Hong et 
al. (2013) used a lot more patients (n AD = 148; n VaD = 60). This could explain the contra-
dictory result. The consequence of the low number of patients was that we had to use multiple 
Mann-Withney u-Tests. Thus, our results must be interpreted with caution because of high 
chances of Type-1 errors. We attempt to reduce this problem by comparing patients with 
aMCI and patients with AD and by comparing patients with VCI and patients with VaD, 
which brings us to the second limitation. A distorted view is presented if low demented pa-
tients were compared with high demented patients. Third, the diagnosis was based on clinical 
findings and structural brain imaging rather than on confirmative pathological data. It is pos-
sible that patients with AD had concomitant VaD pathology and vice versa. This is confirmed 
by the study of Kirson et al., (2013). They found that 16.6% patients with VaD were misdiag-
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nosed with AD. Fourth, these results were not generalizable to patients with severe dementia, 
because we used patients with AD with moderate dementia (MMSE = 18.8) and patients with 
VaD with moderate dementia (MMSE = 21.6). Patients with AD in the other studies were 
mild demented (Hong et al., MMSE= 20.1; Graham et al., MMSE = 24.2). By contrast, the 
VaD patients in the study of Hong et al., (2013) were also moderate demented (MMSE=20.8) 
but in de study of Graham et al., (2004) were the VaD patients not demented (MMSE =25.3). 
Thus, the results of the studies were applicable to patients with different kind of dementia 
severities. 
  Despite these limitations, there are also a few strengths to this study. First, this is be-
lieved to be the first study to find a discriminative validity between patients with aMCI or AD 
and patients with VCI or VaD based on the VAT recognition trial. Furthermore, this study is 
also the first study which evaluated the score difference of the VAT trials for the patients with 
AD and the patients with VaD. Last, this is also the first study which compares the verbal 
15WT recognition trial with the visual VAT recognition trial. 
 
4.3 Recommendations 
  With our results, we still cannot provide scientific input, but only suggestions for fur-
ther research in this area. Further studies should include more patients and especially patients 
with VCI and patients with VaD, this ensures a more powerful result. If there were more pa-
tients included, parametric test could be used instead of non-parametric tests. Another sugges-
tion for further research is using more patients with severe dementia, because none of the pre-
vious studies used severe demented patients. These suggestions hopefully allow for differenti-
ation of the AD patients from the VaD patients and greater generalizability.  
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